EMEA-000715-PIP05-13-M05
Key facts
Invented name |
Otezla
|
Active substance |
apremilast
|
Therapeutic area |
Immunology-Rheumatology-Transplantation
|
Decision number |
P/0353/2022
|
PIP number |
EMEA-000715-PIP05-13-M05
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of Behcet disease
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Amgen Europe B.V.
E-mail: medinfointernational@amgen.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|